174 related articles for article (PubMed ID: 22323092)
1. Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.
Thomas MP; Mahaffey KW; Chiswell K; Cohen M; Kontos MC; Antman EM; Ferguson JJ; Califf RM; Goodman SG; Becker RC
J Thromb Thrombolysis; 2012 Jul; 34(1):114-9. PubMed ID: 22323092
[TBL] [Abstract][Full Text] [Related]
2. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial.
Dillinger JG; Ducrocq G; Elbez Y; Cohen M; Bode C; Pollack C; Nicolau JC; Henry P; Kedev S; Wiviott SD; Sabatine MS; Mehta SR; Steg PG
Circ Cardiovasc Interv; 2018 Jun; 11(6):e006084. PubMed ID: 29895599
[TBL] [Abstract][Full Text] [Related]
3. Impact of anticoagulation on coronary flow in patients with non-ST elevation acute coronary syndrome.
Kang J; Cho YS; Song HY; Kim HJ; Oh IY; Yoon CH; Suh JW; Kim KI; Chung WY; Youn TJ; Chae IH; Choi DJ
Clin Appl Thromb Hemost; 2015 Jan; 21(1):48-57. PubMed ID: 23742947
[TBL] [Abstract][Full Text] [Related]
4. Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux.
Steg PG; Mehta S; Jolly S; Xavier D; Rupprecht HJ; Lopez-Sendon JL; Chrolavicius S; Rao SV; Granger CB; Pogue J; Laing S; Yusuf S
Am Heart J; 2010 Dec; 160(6):1029-34, 1034.e1. PubMed ID: 21146654
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.
Singh KP; Roe MT; Peterson ED; Chen AY; Mahaffey KW; Goodman SG; Harrington RA; Smith SC; Gibler WB; Ohman EM; Pollack CV;
J Thromb Thrombolysis; 2006 Jun; 21(3):211-20. PubMed ID: 16683212
[TBL] [Abstract][Full Text] [Related]
6. A risk score to predict bleeding in patients with acute coronary syndromes.
Mehran R; Pocock SJ; Nikolsky E; Clayton T; Dangas GD; Kirtane AJ; Parise H; Fahy M; Manoukian SV; Feit F; Ohman ME; Witzenbichler B; Guagliumi G; Lansky AJ; Stone GW
J Am Coll Cardiol; 2010 Jun; 55(23):2556-66. PubMed ID: 20513595
[TBL] [Abstract][Full Text] [Related]
7. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
Ferguson JJ; Califf RM; Antman EM; Cohen M; Grines CL; Goodman S; Kereiakes DJ; Langer A; Mahaffey KW; Nessel CC; Armstrong PW; Avezum A; Aylward P; Becker RC; Biasucci L; Borzak S; Col J; Frey MJ; Fry E; Gulba DC; Guneri S; Gurfinkel E; Harrington R; Hochman JS; Kleiman NS; Leon MB; Lopez-Sendon JL; Pepine CJ; Ruzyllo W; Steinhubl SR; Teirstein PS; Toro-Figueroa L; White H;
JAMA; 2004 Jul; 292(1):45-54. PubMed ID: 15238590
[TBL] [Abstract][Full Text] [Related]
8. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J;
Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis.
Galli M; Andreotti F; D'Amario D; Vergallo R; Vescovo GM; Giraldi L; Migliaro S; Ameri P; Porto I; Crea F
Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):43-56. PubMed ID: 31350546
[TBL] [Abstract][Full Text] [Related]
11. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.
Alexander KP; Chen AY; Roe MT; Newby LK; Gibson CM; Allen-LaPointe NM; Pollack C; Gibler WB; Ohman EM; Peterson ED;
JAMA; 2005 Dec; 294(24):3108-16. PubMed ID: 16380591
[TBL] [Abstract][Full Text] [Related]
12. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Harrington RA; Becker RC; Cannon CP; Gutterman D; Lincoff AM; Popma JJ; Steg G; Guyatt GH; Goodman SG
Chest; 2008 Jun; 133(6 Suppl):670S-707S. PubMed ID: 18574276
[TBL] [Abstract][Full Text] [Related]
14. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triage Strategy trial.
Huang X; Chen S; Redfors B; Zhang Y; Souza CF; Mehran R; Bansilal S; Kirtane AJ; Brener SJ; Feite F; Dangas GD; Ben-Yehuda O; Stone GW
Coron Artery Dis; 2020 Jan; 31(1):59-65. PubMed ID: 31809479
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
Heer T; Juenger C; Gitt AK; Bauer T; Towae F; Zahn R; Senges J; Zeymer U;
J Thromb Thrombolysis; 2009 Oct; 28(3):325-32. PubMed ID: 19101783
[TBL] [Abstract][Full Text] [Related]
18. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb.
Lee MS; Wali AU; Menon V; Berkowitz SD; Thompson TD; Califf RM; Topol EJ; Granger CB; Hochman JS
J Thromb Thrombolysis; 2002 Oct; 14(2):91-101. PubMed ID: 12714828
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of anticoagulation in acute coronary syndromes.
Latour-Pérez J; de-Miguel-Balsa E
Pharmacoeconomics; 2012 Apr; 30(4):303-21. PubMed ID: 22409291
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI.
Kikkert WJ; van Nes SH; Lieve KV; Dangas GD; van Straalen J; Vis M; Baan J; Koch KT; de Winter RJ; Piek JJ; Tijssen JG; Henriques JP
Thromb Haemost; 2013 May; 109(5):961-70. PubMed ID: 23446910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
